SEC Form 4 · accession 0001209191-16-145735
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Bradley Cole
Officer — COO
Period of report
Oct 10, 2016
Accepted (ET)
Oct 12, 2016 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 10, 2016 | M | 4,000 | $18.89 | A | 39,426 | D | |
| Common StockF1,F2,F3,F4 | Oct 10, 2016 | S | 4,000 | $30.6756 | D | 35,426 | D | |
| Common Stock | Oct 10, 2016 | M | 4,290 | $23.31 | A | 39,716 | D | |
| Common StockF5,F3,F6,F4 | Oct 10, 2016 | S | 4,290 | $30.5058 | D | 35,426 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F7 | $18.89 | Oct 10, 2016 | M | 4,000 | D | — | Nov 30, 2016 | Common Stock | 0 | 0 | D |
| Employee Stock Option (right to buy)F8 | $23.31 | Oct 10, 2016 | M | 4,290 | D | — | Dec 6, 2017 | Common Stock | 0 | 25,710 | D |
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 7, 2016.
- F2Represents weighted average sale price. Actual sale prices ranged from $30.32 to $30.83.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Includes an aggregate of 18,690 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F5These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 8, 2016.
- F6Represents weighted average sale price. Actual sale prices ranged from $30.07 to $30.75.
- F7The option became exercisable as to 25% of the shares on November 30, 2007, and became exercisable as to 1/48th of the shares each full month thereafter.
- F8The option became exercisable as to 25% of the shares on December 6, 2008, and became exercisable as to 1/48th of the shares each full month thereafter.